Americans with psoriasis and rheumatoid arthritis will have to wait much longer for low-priced copycat versions of their weekly Enbrel injections. Amgen (NASDAQ: AMGN) won an appeals court ruling on ...
Etanercept injectable solution is available as brand-name drugs. It’s not available as a generic drug. Brand names: Enbrel, Erelzi. Etanercept comes only in the form of an injectable solution. It ...
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...
Whether starting or maintaining treatment, the Embark App has multiple features that can help patients on ENBREL throughout their treatment experience. As the healthcare industry continues to evolve ...
The safety of etanercept in this patient population was established through multiple pediatric trials, including a clinical study in 69 children aged 2 to 17 years with moderately to severely active ...
KFF Health News on MSN
Copay assistance is meant to defray patient drug costs. Some insurers keep it instead.
Drugmakers provide financial assistance to help patients afford increasingly expensive medications. But some insurers do not ...
THOUSAND OAKS, Calif., November 12, 2006 -- Amgen (NASDAQ: AMGN) today announced that Enbrel? (etanercept) is the first biologic with published data to show improvements in multiple measures of ...
ENBREL data provide insights from OBSERVE-5, an observational registry designed to examine the use of ENBREL in a real-world setting over five years, as well as on treatment patterns with ENBREL ...
Lupin is introducing Rymti, its first biosimilar in Canada, through its partner Sandoz Canada (Sandoz). Rymti is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile ...
Abbott Laboratories said Wednesday that it will supply an experimental rheumatoid arthritis drug free to patients who need it, a direct challenge to Amgen Inc., which is laboring to end a shortage of ...
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results